CBC Group-backed Peak Pharma to acquire Pariet from Eisai for RMB725m.

CBC Group-backed Peak Pharma, a pharmaceutical company, agreed to acquire Pariet, a proton pump inhibitor, from Eisai, a pharmaceutical company, for RMB725m. "Eisai believes that CBC Group’s proven 'investor-operator' approach and commitment to delivering quality healthcare to a wide range of patients will maximize the value of Pariet in China. The agreement will enable Eisai to strategically reallocate resources to other mid-to-long-term business growth areas so as to continue to make further contributions to address the diversified needs of, and increase the benefits provided to, patients and their families," Eisai statement.